Affordable Access

Publisher Website

Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease

Authors
Journal
Alzheimer s & Dementia
1552-5260
Publisher
Elsevier
Identifiers
DOI: 10.1016/j.jalz.2013.07.003
Keywords
  • Alzheimer'S Disease
  • Hippocampal Volume
  • Mild Cognitive Impairment
  • Alzheimer'S Disease Neuroimaging Initiative

Abstract

Abstract Background Regulatory qualification of a biomarker for a defined context of use provides scientifically robust assurances to sponsors and regulators that accelerate appropriate adoption of biomarkers into drug development. Methods The Coalition Against Major Diseases submitted a dossier to the Scientific Advice Working Party of the European Medicines Agency requesting a qualification opinion on the use of hippocampal volume as a biomarker for enriching clinical trials in subjects with mild cognitive impairment, incorporating a scientific rationale, a literature review and a de novo analysis of Alzheimer's Disease Neuroimaging Initiative data. Results The literature review and de novo analysis were consistent with the proposed context of use, and the Committee for Medicinal Products for Human Use released an opinion in November 2011. Conclusions We summarize the scientific rationale and the data that supported the first qualification of an imaging biomarker by the European Medicines Agency.

There are no comments yet on this publication. Be the first to share your thoughts.